Drug Trial Radar · NCT05776056
Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 5, 2024
Primary completion
Mar 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Posttraumatic stress disorder (PTSD) is frequently accompanied by difficulty concentrating, poor memory, and inability to keep up with tasks, which negatively impacts a person's ability to function at work and in relationships. Currently available treatments do not fully relieve all symptoms. A published research report showed positive evidence that the stimulant medication methylphenidate was beneficial in treating these problems. This study will evaluate the ability of methylphenidate to treat PTSD and associated neurocognitive complaints in Veterans. An innovative feature is the study's N-of-1 design. In this design, every participant will move back and forth every 4-5 weeks between treatment with methylphenidate and treatment with placebo, in random order and under double-blind conditions, over a 20-week period. The investigators will compare the aggregated change in PTSD and neurocognitive symptoms between periods of treatment with methylphenidate versus placebo. Results will help clinicians to better choose the best treatment for Veterans living with PTSD.
Conditions
- Posttraumatic Stress Disorder (PTSD)
Interventions
MethylphenidateDrug
Methylphenidate 10mg will be taken twice daily.
PlaceboDrug
An inactive pill (placebo) will be taken twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PTSD Symptom Checklist for DSM-5 (PCL-5)Time frame: 4 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Birmingham VA Medical Center, Birmingham, AL
Birmingham, Alabama · Recruiting
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama · Recruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.